News on cancer. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-presents-new-preclinical-data-supporting
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
交易進行
>180 up since Dec. outpacing edit and crispr. still looks technically extended免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。